Specialty hub

Rheumatology

Containing dedicated Learning Zones, guidelines, trials and news for related conditions in Rheumatology.

Rheumatology is branch of medicine that deals with the diagnosis and treatment of disorders of connective tissues and joints, many of which are now known to be immune mediated conditions.

Featured Learning Zones

Learning Zone

Anti-TNF biosimilars for rheumatic diseases

Explores unmet needs in rheumatic disease management, including inequities in treatment access, and how anti-TNF biosimilars can help to address this gap.

Learning Zone Homepage

Managing Osteoarthritis-associated Pain

Did you know that treating pain in osteoarthritis (OA) is changing? Discover the burden of OA, emerging therapies and personalised pain management.

Learning Zone Homepage

Optimising anti-TNF treatment using biosimilars

Biosimilars are uniquely placed to change clinical practice in the fields of gastroenterology, rheumatology, and dermatology. The adoption of biosimilars can improve patient access to the most appropriate treatment, at the optimum time, to ensure the best possible long-term disease outcomes.

Rheumatic diseases can be caused by trauma, heredity, genetic abnormality, autoimmune disease, or another underlying condition such as cancer. There are more than 150 different types of rheumatic disorders, including arthritis, rheumatoid and osteoarthritis, gout and lupus.

Diseases in this section

Arthritis

Containing relevant Learning Zones, guidelines, trials and news.

Osteoarthritis

Containing relevant Learning Zones, guidelines, trials and news.

Lupus

Containing relevant Learning Zones, guidelines, trials and news.

Welcome:

Updates in your area
of interest

Articles your peers
are looking at

Bookmarks
saved

Days to your
next event

Related news and insights

Drug news

FDA approval for adalimumab biosimilar Idacio

Fresenius Kabi, a global health care company that specializes in pharmaceuticals, medical technologies, and nutrition products for critical and chronic conditions, announced that the FDA has approved its citrate-free adalimumab biosimilar Idacio for use in the treatment of chronic autoimmune diseases for all eligible indications of the reference product, Humira(adalimumab)

1 mins

Drug news

FDA approves Tymlos for men with osteoporosis.- Radius Health

Radius Health announced that the FDA has approved Tymlos (abaloparatide), a parathyroid hormone related peptide [PTHrP(1-34)] analog, as a treatment to increase bone density in men with osteoporosis at high risk of fracture (defined as a history of osteoporotic fracture or multiple risk factors for fracture), or in patients who have failed or are intolerant to other available osteoporosis therapy.

1 min

Drug news

The Lancet publishes results from two bimekizumab phase III studies in psoriatic arthritis

UCB, announced that The Lancet has published two articles detailing 24-week results from the Phase III BE OPTIMAL study and 16-week results from the Phase III BE COMPLETE study, evaluating the efficacy and safety of bimekizumab in the treatment of adults with active psoriatic arthritis who were biologic-naïve and tumour necrosis factor inhibitor inadequate responders (TNFi-IR), respectively

1 min

See all news

Related Drugs

FDA Hero Banner - Multi-coloured pills and tablets

Hydroxychloroquine Sulfate HYDROXYCHLOROQUINE SULFATE 200 mg/1 RedPharm Drug, Inc.

1 mins

Hydroxychloroquine sulfate HYDROXYCHLOROQUINE SULFATE 200 mg/1 McKesson Corporation dba SKY Packaging

2 mins

Hydroxychloroquine Sulfate HYDROXYCHLOROQUINE SULFATE 300 mg/1 Novitium Pharma LLC

2 mins

Hydroxychloroquine Sulfate HYDROXYCHLOROQUINE SULFATE 200 mg/1 Novitium Pharma LLC

2 mins

Leflunomide LEFLUNOMIDE 20 mg/1 Winthrop U.S.

1 mins

Hydroxychloroquine sulfate HYDROXYCHLOROQUINE SULFATE 200 mg/1 Sun Pharmaceutical Industries, Inc.

2 mins

Hydroxychloroquine Sulfate HYDROXYCHLOROQUINE SULFATE 200 mg/1 Laurus Labs Limited

2 mins

Leflunomide LEFLUNOMIDE 10 mg/1 Winthrop U.S.

1 mins

Hydroxychloroquine Sulfate HYDROXYCHLOROQUINE SULFATE 200 mg/1 Sandoz Inc

2 mins

Hydroxychloroquine sulfate HYDROXYCHLOROQUINE SULFATE 200 mg/1 Zydus Lifesciences Limited

1 mins

Leflunomide LEFLUNOMIDE 20 mg/1 Burel Pharmaceuticals, LLC

1 mins

Leflunomide LEFLUNOMIDE 20 mg/1 Cadila Healthcare Limited

1 mins

Hydroxychloroquine Sulfate HYDROXYCHLOROQUINE SULFATE 200 mg/1 Bryant Ranch Prepack

2 mins

INFLIXIMAB INFLIXIMAB 100 mg/10mL Janssen Biotech, Inc.

6 mins

Leflunomide LEFLUNOMIDE 10 mg/1 Burel Pharmaceuticals, LLC

1 mins

Related Journals

Journal

Pharmacokinetics, pharmacodynamics, and safety of subcutaneous anifrolumab in patients with systemic lupus erythematosus, active skin disease, and high type I interferon gene signature: a multicentre, randomised, double-blind, placebo-controlled, phase 2

3 mins

Journal

Anifrolumab, a monoclonal antibody to the type I interferon receptor subunit 1, for the treatment of systemic lupus erythematosus: an overview from clinical trials

1 mins

Journal

Diagnostic value of TWEAK for predicting active lupus nephritis in patients with systemic lupus erythematosus: a systematic review and meta-analysis

1 mins

Journal

The Association between Interleukin-6 Gene Polymorphisms and Risk of Systemic Lupus Erythematosus: A Meta-analysis with Trial Sequential Analysis

1 mins

Journal

Low-dose glucocorticoid should be withdrawn or continued in systemic lupus erythematosus? A systematic review and meta-analysis on risk of flare and damage accrual

1 mins

Journal

The risk of infections in adult patients with systemic lupus erythematosus: systematic review and meta-analysis

1 mins

Journal

Risk factors for mortality of diffuse alveolar hemorrhage in systemic lupus erythematosus: a systematic review and meta-analysis

1 mins

Journal

Maternal and fetal complications associated with systemic lupus erythematosus: An updated meta-analysis of the most recent studies (2017-2019)

1 mins

Journal

Systematic review and meta-analysis of HPV vaccination in women with systemic lupus erythematosus (SLE)

1 mins

Journal

Association of systemic lupus erythematosus with hearing loss: a systemic review and meta-analysis

1 mins

Related Guidelines

Guideline

2019 update of the EULAR recommendations for the management of systemic lupus erythematosus

The updated recommendations provide physicians and patients with updated consensus guidance on the management of SLE, combining evidence-base and expert-opinion.

1 mins

Guideline

NRAS position paper on biosimilar medicines Updated February, 2019

In this position paper we set out our recommendations for a national best practice approach to be taken.

1 min

Guideline

EULAR recommendations for the use of imaging in the clinical management of peripheral joint osteoarthritis

These evidence-based recommendations and related research agenda provide the basis for sensible use of imaging in routine clinical assessment of people with OA.

1 min

See all guidelines